MME and breast carcinoma: In total, only 2% of breast cancers of the different molecular subtypes tested (8/438 of the TMA) displayed a positive (≥20% CD10+ cells) intratumoral CD10 staining, while no significant difference between breast tumor subtypes was observed for CD10 staining in the stroma (Supplementary Table S2).